Medical technology innovator **Endogenex** has officially announced the completion of patient recruitment for its pivotal **ReCET** clinical trial. This milestone marks a significant step forward in the development of an endoscopic treatment designed to manage **glycemic control** in patients suffering from **Type 2 diabetes**.
The **ReCET** procedure—short for **Re-cellularization via Electroporation Therapy**—is a minimally invasive approach that targets the **duodenal mucosa**. By utilizing **pulsed electric fields** to perform **duodenal mucosal resurfacing**, the technology aims to improve the metabolic health of patients who are inadequately controlled by diet, lifestyle modifications, or oral medications.
By focusing on the **duodenum**, the study investigates whether altering the cellular landscape of the upper small intestine can restore the body’s natural hormonal responses to glucose. This is a departure from traditional pharmacological interventions, which often focus exclusively on insulin production or glucose absorption. Instead, the **Endogenex** approach addresses the underlying signaling pathways that are frequently dysregulated in individuals living with metabolic diseases.
The completion of enrollment is a critical phase in the study’s roadmap toward regulatory review. With the full cohort of participants now engaged, the research team can proceed with collecting and analyzing long-term outcome data. The primary endpoints of the study focus on **HbA1c reduction** and the potential for patients to reduce or eliminate their reliance on daily **insulin therapy**.
If the clinical data successfully demonstrates safety and efficacy, **ReCET** could offer a transformative alternative for patients who struggle with the side effects or complexities of conventional diabetes management. Clinicians are particularly interested in the durability of the **metabolic improvements** observed following a single outpatient procedure, which would represent a major shift in the current standards of care.
The medical community is now awaiting the final data readout, which will be essential for potential regulatory submissions and broader clinical adoption. As the industry continues to prioritize **neuromodulation** and **endoscopic metabolic therapies**, the progress of this trial remains a focal point for researchers specializing in **diabetology** and **gastroenterology**.
The successful conclusion of this recruitment phase underscores the growing interest in interventional technologies that target the gut-brain axis to manage chronic metabolic disorders. Further updates from the trial are expected as the final participants complete their mandatory follow-up assessments.
